For Immediate Release
Chicago, IL – January 24, 2012 – Zacks Equity Research highlights Caterpillar, Inc. (CAT - Free Report) as the Bull of the Day and NII Holdings, Inc. (NIHD - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Lowe’s Companies Inc. (LOW - Free Report) , Home Depot Inc. (HD - Free Report) and St. Jude Medical (STJ - Free Report) .
Full analysis of all these stocks is available at https://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
Bull of the Day:
Caterpillar, Inc. (CAT - Free Report) posted an impressive third quarter with record EPS of $1.93 and sales of $14.6 billion driven by increased machine demand and continued economic growth. Results were ahead of Zacks Consensus Estimates. With the Bucyrus acquisition, the company is positioned to be the #1 mining equipment manufacturer in the U.S. with a strong footing in China and India, the major mining markets.
Caterpillar's financial position continues to strengthen through the first nine months of the year. Caterpillar's cash flow for the period is an all-time high and better than the company's full-year results so far.
Furthermore, the company's order backlog has steadily increased throughout the year and is at a record level, which holds promise for the year ahead. We upgrade our recommendation from Neutral to Outperform and set a target price of $127.
Bear of the Day:
We downgrade our recommendation on NII Holdings, Inc. (NIHD - Free Report) to Underperform backed by our assessment that the company s nightmare will continue in the near future. NII Holdings reported dismal financial results for the third quarter of 2011. Both the top line and bottom line were well below the Zacks Consensus Estimates.
Management has slashed its fiscal 2011 financial outlook, mainly driven by the volatile macro-economic condition coupled with significant depreciation of several Latin American currencies in comparison with U.S. dollars. Moreover, stiff competitive scenarios in Latin American markets are other impediments for such a reduced outlook.
We believe intensifying competition and increased promotional expenses may reduce the company's near-term growth opportunities. We do not find any immediate catalysts and expect NII Holdings to report weak financial results for the company's 4th quarter.
Latest Posts on the Zacks Analyst Blog:
Lowe’s Balancing Act
The growth of home improvement companies is directly proportional to the housing market cycles, which in turn is closely related with the prevailing economic conditions. A tremor at one end obviously makes its rippling effects evident on the other end too.
Remember the subprime crisis, which destabilized the U.S. housing market? Thus Lowe’s Companies Inc. (LOW - Free Report) , being the world’s second largest home improvement retailer, will have to walk the tight rope.
A Look at Guidance
Lowe’s expects fourth-quarter 2011 earnings in the range of 20 cents to 23 cents a share. For fiscal 2011, management expects earnings between $1.57 and $1.60 per share, excluding charges of 20 cents related to store closings and discontinued operations. The current Zacks Consensus Estimate for the fourth quarter and fiscal 2011 are 23 cents and $1.61 per share.
Management now expects sales to increase approximately 8% in the fourth quarter and between 2% and 3% in fiscal 2011. Earlier, Lowe’s had forecasted fiscal 2011 sales to increase by approximately 2%. Lowe’s expects comparable-store sales to remain flat or up 1% in the fourth quarter but to decline by 1% in fiscal 2011.
Challenging Economy & Competition
Heavy job losses and reduced access to credit have lead to a sharp fall in consumer discretionary spending on big-ticket items. With the global economic environment still struggling, we believe that spending on big remodeling projects will likely remain under pressure until the housing market stabilizes and consumer-spending rebounds.
Lowe’s in the home improvement retailing business faces stiff competition from The Home Depot Inc. (HD - Free Report) , Sherwin-Williams Company and other home supply retailers on attributes such as location, price and quality of merchandise, in-stock consistency, merchandise assortments, and customer service. This may weigh upon the company’s results.
St. Just Halts FAME II Enrollment
Medical devices major St. Jude Medical (STJ - Free Report) will stop enrolling new patients in its FAME II clinical trial following positive results from an interim analysis.
The independent data safety monitoring board (“DSMB”) recommended investigators to halt patient enrollment in the study following the impressive results which have shown statistically significant reduction in the need for hospital readmission and urgent revascularization when fractional flow reserve (“FFR”)-guided assessment is used in treating patients with coronary artery disease.
FFR is an index that identifies and measures the severity of coronary artery narrowing. It specifically locates the coronary narrowings which are responsible for occluding blood flow to a patient's heart muscle and directs the surgeons to identify the lesions requiring stenting. The approach is believed to help rein in healthcare costs and improve patient outcome.
The company-sponsored FAME II trial is evaluating the use of St. Jude’s PressureWire FFR devices during the treatment of patient with stable coronary artery disease. The objective of the trial is to study the role of FFR in treating this condition by comparing FFR-guided percutaneous coronary intervention (“PCI”) plus optimal medical therapy (“OMT”) with OMT alone.
The DSMB considered it unethical to continue randomize patients to OMT alone as patients experienced a highly statistically significant increased risk of hospital readmission and urgent revascularization. The DSMB advised St. Jude to stop enrolling patients in the FAME II study given the higher risk of major adverse cardiac events in patients randomized to OMT alone versus “FFR-guided PCI plus OMT”. The board concluded that this difference was highly unlikely to change with the enrollment of additional patients.
Get the full analysis of all these stocks by going to https://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting https://at.zacks.com/?id=7158.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at https://at.zacks.com/?id=4582.
Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339